探索不同甲状腺癌患者对多重原发性瘤的敏感性
Laura Valerio1, Silvia Cantara1, Elisa Mattii1
1Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
Diagnostics (Basel, Switzerland)
|June 27, 2024
概括
血液白细胞中端粒长度较短与差异化甲状腺癌 (DTC) 患者多重原发性瘤 (MPT) 的风险增加有关. 这一发现表明端粒长度可能作为MPT在DTC发展的预后标志物.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 差异化甲状腺癌 (DTC) 患者有发展多重原发性瘤 (MPT) 的风险.
- 缩短端粒长度与癌症的发展有关.
- 端粒长度在DTC患者MPT发展中的作用尚不清楚.
研究的目的:
- 研究血液白细胞中短端粒长度与DTC患者MPT风险之间的相关性.
- 确定端粒长度是否是DTC中MPT发展的预测因素.
主要方法:
- 对167名DTC患者和105名健康对照者的回顾性评估.
- 在外周血液白细胞中测量相对端粒长度 (RTL).
- 年龄相匹配的研究小组进行比较.
主要成果:
- 在DTC患者和健康受试者之间的RTL显著差异 (p < 0.0001).
- 与对照组相比,在有或没有MPT的DTC患者中观察到较短的端粒.
- RTL和家族DTC是MPT存在的独立预测因素 (分别为p=0.018和p=0.032).
结论:
- 相对端粒长度可能在预测DTC患者MPT发展方面发挥作用.
- 这些发现有助于理解MPT在DTC中的遗传机制.
- 相对端粒长度可能是DTC中MPT的潜在预后标志物.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


